# Bausch + Lomb Corporation (BLCO) fundamentals

Data as of 2026-09-08. NYSE, United States. Sector: Healthcare. Price $18.04, market value $6.4 billion.

## Valuation
- **P/E (trailing): n/a** (negative earnings). Bausch + Lomb Corporation reported negative earnings over the last twelve months, so the P/E is not meaningful; use price-to-sales, EV/EBITDA and free-cash-flow yield instead.
- **Price / sales: 1.2×**. Each dollar of revenue is priced at 1.2×.
- **Price / book: 1.0×**. The shares trade below book value, which can signal a bargain or a balance sheet the market doubts.
- **EV / EBITDA: 15.2×**. Enterprise value is 15.2× operating earnings before depreciation, the multiple that ignores how the company is financed.
- **Free-cash-flow yield: 2.1%** (5-yr avg -0.6%). Free cash flow equals 2.1% of the market value, above its five-year average of -0.6%, so the shares are cheaper on cash than they have usually been.

## Profitability
- **Operating margin: 6.1%**. 6.1% of revenue is left after running the business.
- **Net margin: -7.1%**. The company reported a net loss over the last twelve months.
- **Return on equity: -5.6%**. Return on equity is negative because earnings are negative.
- **Return on invested capital: 2.3%**. Return on all capital, debt included, is 2.3%: close to or below the cost of capital, so growth may not create value.
- **Return on assets: -1.2%**. Each dollar of assets produces -1.2% of profit.

## Growth
- **Revenue growth (1 yr): 6.5%** (3-yr 10.6%/yr). Revenue grew 6.5% over the last year.
- **EPS growth (1 yr): -13.3%**. Earnings per share fell 13.3%, slower than revenue, so margins compressed.

## Financial health
- **Debt to equity: 0.79**. Debt is 0.79 times equity, moderate leverage.
- **Net debt / EBITDA: 6.4×**. It would take 6.4 years of operating earnings to repay net borrowings, above the 3× level most lenders treat as comfortable.
- **Current ratio: 1.55** (quick 1.04). Current assets cover the next year's liabilities 1.55 times.
- **Altman Z-score: 1.66**. A Z-score of 1.66 is in the distress zone, a signal to examine the balance sheet closely.
- **Piotroski F-score: 3/9**. 3 of 9 checks pass: weak or deteriorating financials.

## Dividends
- **Dividend: none**. Bausch + Lomb Corporation does not currently pay a dividend.

## Analyst view
- **Analyst consensus: buy** (12 analysts). 12 analysts cover Bausch + Lomb Corporation; the consensus is buy, with an average price target of $18.63 (+3% from the current price). Analyst opinion is shown for context; it is not part of the Fundamental Score.

## Price and momentum
- **Total return (1 yr): 23.6%** (YTD 5.6%, 3-mo 16.7%). The shares are up 23.6% over twelve months including dividends.
- **From 52-week high: -4.6%** (31.1% above the low). Trading within 5% of its 52-week high.
- **200-day average: above**. The price sits above its 200-day moving average, the usual definition of an uptrend.
- **RSI (14-day): 69**. An RSI of 69 is neutral.
- **Beta (1 yr): 0.96** (volatility 30%). Beta of 0.96 against the S&P 500: the shares move roughly with the market.

Live score and charts: https://foliofundamentals.com/analyzer?s=BLCO · Page: https://foliofundamentals.com/stocks/blco

Not investment advice.